Publications by authors named "Anais Razurel"
Eur J Hosp Pharm
January 2021
Article Synopsis
- SARS-CoV-2, responsible for COVID-19, can lead to severe lung issues due to hyperinflammation, often treated off-label with Tocilizumab (TCZ), an IL-6 receptor blocker.
- A study of 44 COVID-19 patients compared 22 treated with TCZ to 22 controls, finding that the TCZ group had a lower average respiratory rate and a trend towards less need for intubation.
- Results showed TCZ treatment significantly reduced CRP levels, indicating decreased inflammation, although cytolysis occurred in many patients without noticeable clinical effects.
